CLC-3 channels in cancer (Review)

Oncology Reports

Volumn 33, Issue 2, 2015, Pages 507-514

  Hong, Sen ^a,b   Bi, Miaomiao ^c   Wang, Lei ^b   Kang, Zhenhua ^b   Ling, Limian ^b   Zhao, Chunyan ^a  

^a JILIN UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^c CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Apoptosis; Cancer; Chemotherapeutic resistance; Chloride channel; CLC 3; Proliferation

Indexed keywords

ANION CHANNEL; BUFADIENOLIDE DERIVATIVE; CHLOROTOXIN; CLC 3 PROTEIN; SCORPION VENOM; UNCLASSIFIED DRUG; VOLTAGE GATED CHLORIDE CHANNEL; VOLUME REGULATED ANION CHANNEL; ANTINEOPLASTIC AGENT; CHLORIDE CHANNEL; CLC-3 CHANNEL;

APOPTOSIS; CANCER CELL; CANCER RESISTANCE; CANCER THERAPY; CELL PROLIFERATION; DRUG TARGETING; GLIOMA; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NASOPHARYNX CARCINOMA; NEUROENDOCRINE TUMOR; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; METABOLISM; NEOPLASMS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CHLORIDE CHANNELS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS;

EID: 84919432479     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3615     Document Type: Review

References (102)

1. Marban E: Cardiac channelopathies. Nature 415: 213-218, 2002.
2. Platt D and Griggs R: Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias. Curr Opin Neurol 22: 524-531, 2009.
3. Catterall WA, Dib-Hajj S, Meisler MH and Pietrobon D: Inherited neuronal ion channelopathies: new windows on complex neurological diseases. J Neurosci 28: 11768-11777, 2008.
4. Planells-Cases R and Jentsch TJ: Chloride channelopathies. biochim biophys Acta 1792: 173-189, 2009.
5. Rolim AL, Lindsey SC, Kunii IS, et al: Ion channelopathies in endocrinology: recent genetic fndings and pathophysiological insights. Arq bras Endocrinol metabol 54: 673-681, 2010.
6. Lehen'kyi V, Shapovalov G, Skryma R and Prevarskaya N: Ion channels and transporters in cancer. 5. Ion channels in control of cancer and cell apoptosis. Am J Physiol Cell Physiol 301: C1281-C1289, 2011.
7. Kunzelmann K: Ion channels and cancer. J membr biol 205: 159-173, 2005.
8. Hoffmann EK and Lambert IH: Ion channels and transporters in the development of drug resistance in cancer cells. Philos Trans R Soc Lond B Biol Sci 369: 20130109, 2014.
9. Lang F and Stournaras C: Ion channels in cancer: future perspectives and clinical potential. Philos Trans R Soc Lond B Biol Sci 369: 20130108, 2014.
10. Li M and Xiong ZG: Ion channels as targets for cancer therapy. Int J Physiol Pathophysiol Pharmacol 3: 156-166, 2011.
11. Arcangeli A, Crociani O, Lastraioli E, Masi A, Pillozzi S and Becchetti A: Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. Curr med Chem 16: 66-93, 2009.
12. Conti M: Targeting ion channels for new strategies in cancer diagnosis and therapy. Curr Clin Pharmacol 2: 135-144, 2007.
13. Bortner CD and Cidlowski JA: Ion channels and apoptosis in cancer. Philos Trans R Soc Lond B Biol Sci 369: 20130104, 2014.
14. Becchetti A, Munaron L and Arcangeli A: The role of ion channels and transporters in cell proliferation and cancer. Front Physiol 4: 312, 2013.
15. Prevarskaya N, Skryma R, Bidaux G, Flourakis M and Shuba Y: Ion channels in death and differentiation of prostate cancer cells. Cell Death Differ 14: 1295-1304, 2007.
16. Lang F, Foller M, Lang KS, et al: Ion channels in cell proliferation and apoptotic cell death. J membr biol 205: 147-157, 2005.
17. Lang F, Foller M, Lang K, et al: Cell volume regulatory ion channels in cell proliferation and cell death. methods Enzymol 428: 209-225, 2007.
18. Urrego D, Tomczak AP, Zahed F, Stuhmer W and Pardo LA: Potassium channels in cell cycle and cell proliferation. Philos Trans R Soc Lond B Biol Sci 369: 20130094, 2014.
19. Blackiston DJ, McLaughlin KA and Levin M: Bioelectric controls of cell proliferation: ion channels, membrane voltage and the cell cycle. Cell Cycle 8: 3527-3536, 2009.
20. Abdul M and Hoosein N: Expression and activity of potassium ion channels in human prostate cancer. Cancer Lett 186: 99-105, 2002.
21. - channels. Gen Pharmacol 27: 1131-1140, 1996.
22. Shen MR, Yang TP and Tang MJ: A novel function of bCL-2 overexpression in regulatory volume decrease. Enhancing swelling-activated Ca(2+) entry and Cl(-) channel activity. J biol Chem 277: 15592-15599, 2002.
23. Duan DD: The CLC-3 chloride channels in cardiovascular disease. Acta Pharmacol Sin 32: 675-684, 2011.
24. Mao J, Chen L, Xu B, et al: Suppression of CLC-3 channel expression reduces migration of nasopharyngeal carcinoma cells. biochem Pharmacol 75: 1706-1716, 2008.
25. - current and CLC-3 expression in human prostate cancer epithelial cells. Cancer Res 64: 4841-4848, 2004.
26. Habela CW, Olsen ML and Sontheimer H: CLC3 is a critical regulator of the cell cycle in normal and malignant glial cells. J Neurosci 28: 9205-9217, 2008.
27. Wang GX, Hatton WJ, Wang GL, et al: Functional effects of novel anti-CLC-3 antibodies on native volume-sensitive osmolyte and anion channels in cardiac and smooth muscle cells. Am J Physiol heart Circ Physiol 285: h1453-h1463, 2003.
28. - currents by functional anti-CLC-3 antibody in native bovine non-pigmented ciliary epithelial cells. Invest Ophthalmol Vis Sci 46: 948-955, 2005.
29. - concentration through volume-regulated CLC-3 chloride channels in A10 vascular smooth muscle cells. J biol Chem 280: 7301-7308, 2005.
30. Duran C, Thompson CH, Xiao Q and Hartzell HC: Chloride channels: often enigmatic, rarely predictable. Annu Rev Physiol 72: 95-121, 2010.
31. Guzman RE, Grieschat M, Fahlke C and Alekov AK: CLC-3 is an intracellular chloride/proton exchanger with large voltage-dependent nonlinear capacitance. ACS Chem Neurosci 4: 994-1003, 2013.
32. Scheel O, Zdebik AA, Lourdel S and Jentsch TJ: Voltage-dependent electrogenic chloride/proton exchange by endosomal CLC proteins. Nature 436: 424-427, 2005.
33. Picollo A and Pusch M: Chloride/proton antiporter activity of mammalian CLC proteins CLC-4 and CLC-5. Nature 436: 420-423, 2005.
34. Hara-Chikuma M, Yang B, Sonawane ND, Sasaki S, Uchida S and Verkman AS: CLC-3 chloride channels facilitate endosomal acidification and chloride accumulation. J biol Chem 280: 1241-1247, 2005.
35. Rajagopal A and Simon SM: Subcellular localization and activity of multidrug resistance proteins. mol biol Cell 14: 3389-3399, 2003.
36. Weylandt KH, Nebrig M, Jansen-Rosseck N, et al: CLC-3 expression enhances etoposide resistance by increasing acidif-cation of the late endocytic compartment. mol Cancer Ther 6: 979-986, 2007.
37. Su J, Xu Y, Zhou L, et al: Suppression of chloride channel 3 expression facilitates sensitivity of human glioma u251 cells to cisplatin through concomitant inhibition of Akt and autophagy. Anat Rec (hoboken) 296: 595-603, 2013.
38. Xu Y, Zheng H, Kang JS, et al: 5-Nitro-2-(3-phenylpropylamino) benzoic acid induced drug resistance to cisplatin in human eryth-roleukemia cell lines. Anat Rec (hoboken). 294: 945-952, 2011.
39. Xu B, Mao J, Wang L, et al: CLC-3 chloride channels are essential for cell proliferation and cell cycle progression in nasopharyngeal carcinoma cells. Acta biochim biophys Sin (Shanghai) 42: 370-380, 2010.
40. Zhang H, Zhu L, Zuo W, et al: The CLC-3 chloride channel protein is a downstream target of cyclin D1 in nasopharyngeal carcinoma cells. Int J biochem Cell biol 45: 672-683, 2013.
41. Sontheimer H: An unexpected role for ion channels in brain tumor metastasis. Exp biol med (maywood) 233: 779-791, 2008.
42. Wang L, Ma W, Zhu L, et al: CLC-3 is a candidate of the channel proteins mediating acid-activated chloride currents in nasopha-ryngeal carcinoma cells. Am J Physiol Cell Physiol 303: C14-C23, 2012.
43. Li M, Wu DB and Wang J: Effects of volume-activated chloride channels on the invasion and migration of human endometrial cancer cells. Eur J Gynaecol Oncol 34: 60-64, 2013.
44. Wen PY and Kesari S: Malignant gliomas in adults. N Engl J med 359: 492-507, 2008.
45. Lui VC, Lung SS, Pu JK, Hung KN and Leung GK: Invasion of human glioma cells is regulated by multiple chloride channels including CLC-3. Anticancer Res 30: 4515-4524, 2010.
46. Olsen ML, Schade S, Lyons SA, Amaral MD and Sontheimer H: Expression of voltage-gated chloride channels in human glioma cells. J Neurosci 23: 5572-5582, 2003.
47. 1 receptor modulation of C6 glioma cell migration. Neurosci Lett 497: 80-84, 2011.
48. Montana V and Sontheimer H: Bradykinin promotes the chemotactic invasion of primary brain tumors. J Neurosci 31: 4858-4867, 2011.
49. 2+/calmodulin-dependent protein kinase II (CamKII) in human malignant glioma. J Biol Chem 285: 11188-11196, 2010.
50. 2+/calmodulin-dependent protein kinase. J Biol Chem 276: 20093-20100, 2001.
51. Cuddapah VA, Turner KL, Seifert S and Sontheimer H: Bradykinin-induced chemotaxis of human gliomas requires the activation of KCa3.1 and CLC-3. J Neurosci 33: 1427-1440, 2013.
52. Habela CW and Sontheimer H: Cytoplasmic volume condensation is an integral part of mitosis. Cell Cycle 6: 1613-1620, 2007.
53. Cuddapah VA, Habela CW, Watkins S, Moore LS, Barclay TT and Sontheimer H: Kinase activation of CLC-3 accelerates cyto-plasmic condensation during mitotic cell rounding. Am J Physiol Cell Physiol 302: C527-C538, 2012.
54. Wang LW, Chen LX and Jacob T: CLC-3 expression in the cell cycle of nasopharyngeal carcinoma cells. Sheng Li Xue bao 56: 230-236, 2004.
55. Ye D, Zhang HF, Zhu LY, Wang LW and Chen LX: CLC-3 siRNA inhibits regulatory volume decrease in nasopharyngeal carcinoma cells. Nan Fang Yi Ke Da Xue Xue bao 31: 216-220, 2011 (In Chinese).
56. Yang L, Ye D, Ye W, et al: CLC-3 Is A main component of background chloride channels activated under isotonic conditions by autocrine ATP in nasopharyngeal varcinoma cells. J Cell Physiol 226: 2516-2526, 2011.
57. Zhu L, Yang H, Zuo W, et al: Differential expression and roles of volume-activated chloride channels in control of growth of normal and cancerous nasopharyngeal epithelial cells. biochem Pharmacol 83: 324-334, 2012.
58. Raghunand N, Martinez-Zaguilan R, Wright SH and Gillies RJ: ph and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. biochem Pharmacol 57: 1047-1058, 1999.
59. Hoffmann EK, Lambert IH and Pedersen SF: Physiology of cell volume regulation in vertebrates. Physiol Rev 89: 193-277, 2009.
60. Lang F: Mechanisms and signifcance of cell volume regulation. J Am Coll Nutr 26: S613-S623, 2007.
61. Sardini A, Amey JS, Weylandt KH, Nobles M, Valverdez MA and Higgins CF: Cell volume regulation and swelling-activated chloride channels. Biochim biophys Acta 1618: 153-162, 2003.
62. Wondergem R, Gong W, Monen SH, et al: Blocking swelling-activated chloride current inhibits mouse liver cell proliferation. J Physiol 532: 661-672, 2001.
63. - channels in macro-vascular endothelial cells. Br J Pharmacol 121: 547-555, 1997.
64. - currents and intracellular CLC-3 are involved in proliferation of human pulmonary artery smooth muscle cells. J hypertens 32: 318-330, 2014.
65. Shen MR, Droogmans G, Eggermont J, Voets T, Ellory JC and Nilius B: Differential expression of volume-regulated anion channels during cell cycle progression of human cervical cancer cells. J Physiol 529: 385-394, 2000.
66. Duan D, Winter C, Cowley S, Hume JR and Horowitz B: Molecular identifcation of a volume-regulated chloride channel. Nature 390: 417-421, 1997.
67. Stobrawa SM, Breiderhoff T, Takamori S, Engel D, Schweizer M, Zdebik AA, Bösl MR, Ruether K, Jahn H, Draguhn A, Jahn R and Jentsch TJ: Disruption of CLC-3, a chloride channel expressed on synaptic vesicles, leads to a loss of the hippocampus. Neuron 29: 185-196, 2001.
68. -/- mice. J Physiol 557: 439-456, 2004.
69. Xiong D, Heyman NS, Airey J, et al: Cardiac-specifc, inducible CLC-3 gene deletion eliminates native volume-sensitive chloride channels and produces myocardial hypertrophy in adult mice. J Mol Cell Cardiol 48: 211-219, 2010.
70. Wang GL, Wang XR, Lin MJ, He H, Lan XJ and Guan YY: Defciency in CLC-3 chloride channels prevents rat aortic smooth muscle cell proliferation. Circ Res 91: E28-E32, 2002.
71. Tang YB, Liu YJ, Zhou JG, Wang GL, Qiu QY and Guan YY: Silence of CLC-3 chloride channel inhibits cell proliferation and the cell cycle via G/S phase arrest in rat basilar arterial smooth muscle cells. Cell Prolif 41: 775-785, 2008.
72. Rouzaire-Dubois B, O'Regan S and Dubois JM: Cell size-dependent and independent proliferation of rodent neuro-blastoma x glioma cells. J Cell Physiol 203: 243-250, 2005.
73. Dubois JM and Rouzaire-Dubois B: The infuence of cell volume changes on tumour cell proliferation. Eur biophys J 33: 227-232, 2004.
74. Van der wijk T, De Jonge HR and Tilly BC: Osmotic cell swelling-induced ATP release mediates the activation of extracellular signal-regulated protein kinase (Erk)-1/2 but not the activation of osmo-sensitive anion channels. Biochem J 343: 579-586, 1999.
75. Sadoshima J, Qiu Z, Morgan JP and Izumo S: Tyrosine kinase activation is an immediate and essential step in hypotonic cell swelling-induced ERK activation and c-fos gene expression in cardiac myocytes. EmbO J 15: 5535-5546, 1996.
76. Modi PK, Komaravelli N, Singh N and Sharma P: Interplay between mEK-ERK signaling, cyclin D1 and cyclin-dependent kinase 5 regulates cell cycle reentry and apoptosis of neurons. Mol Biol Cell 23: 3722-3730, 2012.
77. Cohen JD, Gard JM, Nagle RB, Dietrich JD, Monks TJ and Lau SS: ERK crosstalks with 4EbP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma. Toxicol Sci 124: 75-87, 2011.
78. Ravenhall C, Guida E, Harris T, Koutsoubos V and Stewart A: The importance of ERK activity in the regulation of cyclin D1 levels and DNA synthesis in human cultured airway smooth muscle. Br J Pharmacol 131: 17-28, 2000.
79. + effux in the activation of apoptosis. J Biol Chem 272: 32436-32442, 1997.
80. Eggermont J, Trouet D, Carton I and Nilius B: Cellular function and control of volume-regulated anion channels. Cell Biochem biophys 35: 263-274, 2001.
81. Pedersen SF, Hoffmann EK and Novak I: Cell volume regulation in epithelial physiology and cancer. Front Physiol 4: 233, 2013.
82. Stutzin A and Hoffmann EK: Swelling-activated ion channels: functional regulation in cell-swelling, proliferation and apoptosis. Acta Physiol (Oxf) 187: 27-42, 2006.
83. Maeno E, Ishizaki Y, Kanaseki T, Hazama A and Okada Y: Normotonic cell shrinkage because of disordered volume regulation is an early prerequisite to apoptosis. Proc Natl Acad Sci uSA 97: 9487-9492, 2000.
84. Okada Y, Shimizu T, Maeno E, Tanabe S, Wang X and Takahashi N: Volume-sensitive chloride channels involved in apoptotic volume decrease and cell death. J membr biol 209: 21-29, 2006.
85. Qian Y, Du YH, Tang YB, et al: CLC-3 chloride channel prevents apoptosis induced by hydrogen peroxide in basilar artery smooth muscle cells through mitochondria dependent pathway. Apoptosis 16: 468-477, 2011.
86. Cheng G, Shao Z, Chaudhari B and Agrawal DK: Involvement of chloride channels in TGF-beta1-induced apoptosis of human bronchial epithelial cells. Am J Physiol Lung Cell mol Physiol 293: L1339-1347, 2007.
87. Zhang HN, Zhou JG, Qiu QY, Ren JL and Guan YY: CLC-3 chloride channel prevents apoptosis induced by thapsigargin in PC12 cells. Apoptosis 11: 327-336, 2006.
88. Zhang H, Li H, Yang L, et al: The CLC-3 chloride channel associated with microtubules is a target of paclitaxel in its induced-apoptosis. Sci Rep 3: 2615, 2013.
89. Liu J, Zhang D, Li Y, et al: Discovery of bufadienolides as a novel class of CLC-3 chloride channel activators with antitumor activities. J Med Chem 56: 5734-5743, 2013.
90. Lin Y, Fukuchi J, Hiipakka RA, Kokontis JM and Xiang J: up-regulation of bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage. Cell Res 17: 531-536, 2007.
91. Yang YD, Cho H, Koo JY, et al: TmEm16A confers receptor-activated calcium-dependent chloride conductance. Nature 455: 1210-1215, 2008.
92. - channel function and cell volume regulation in AGS cells. Am J Physiol Gastrointest Liver Physiol 285: G938-948, 2003.
93. Gomez-Varela D, Zwick-Wallasch E, Knotgen H, et al: Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res 67: 7343-7349, 2007.
94. Debin JA and Strichartz GR: Chloride channel inhibition by the venom of the scorpion Leiurus quinquestriatus. Toxicon 29: 1403-1408, 1991.
95. Deshane J, Garner CC and Sontheimer H: Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem 278: 4135-4144, 2003.
96. Qin C, He B, Dai W, et al: The impact of a chlorotoxin-modifed liposome system on receptor mmP-2 and the receptor-associated protein CLC-3. Biomaterials 35: 5908-5920, 2014.
97. Mamelak AN, Rosenfeld S, Bucholz R, et al: Phase I single-dose study of intracavitary-administered iodine-131-Tm-601 in adults with recurrent high-grade glioma. J Clin Oncol 24: 3644-3650, 2006.
98. Newman RA, Yang P, Pawlus AD and Block KI: Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 8: 36-49, 2008.
99. Abdel-Rahman MA, Ahmed SH and Nabil ZI: In vitro cardio-toxicity and mechanism of action of the Egyptian green toad Bufo viridis skin secretions. Toxicol In Vitro 24: 480-485, 2010.
100. Barrueto F JR, Kirrane BM, Cotter BW, Hoffman RS and Nelson LS: Cardioactive steroid poisoning: a comparison of plant-and animal-derived compounds. J Med Toxicol 2: 152-155, 2006.
101. Hu K, Zhu L, Liang H, Hu F and Feng J: Improved antitumor effcacy and reduced toxicity of liposomes containing bufadi-enolides. Arch Pharm Res 34: 1487-1494, 2011.
102. Yoshikawa M, Uchida S, Ezaki J, et al: CLC-3 defciency leads to phenotypes similar to human neuronal ceroid lipofuscinosis. Genes Cells 7: 597-605, 2002.